NCT05018702
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have been previously treated with Herceptin/trastuzumab, taxane, and/or EGFR-TKI-containing regimens (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib)
Exclusions: Patients with previous treatment of Kadcyla/T-DM1 or other HER2 antibody drug conjugates
https://ClinicalTrials.gov/show/NCT05018702